Treats Non-24. ANDA 211601, held by Teva Pharms USA Inc. Tasimelteon.
As of Nov 16, 2026, ANDA 211601 (Tasimelteon), held by Teva Pharms USA Inc, was first approved by FDA on Dec 12, 2022, with 0 approved supplements and 0 published complete response letters.
Tasimelteon is a melatonin receptor agonist. Tasimelteon capsules are indicated for the treatment of: Non-24-Hour Sleep-Wake Disorder (Non-24) in adults 1.1 Non-24-Hour Sleep-Wake Disorder (Non-24) Tasimelteon capsules are indicated for the treatment of Non-24 in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 12, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tasimelteon20MG · capsule;oral | Tasimelteon | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters